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Summary​ : Cancer-associated fibroblasts (CAF) contribute to tumour       
progression but the mechanisms by which they are generated are poorly           
understood. Here we show microRNA-145 inhibits CAF formation by acting          
in a negative feedback loop with TGF-β1. This pathway may offer           
therapeutic opportunities. 
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Abstract 
The dissemination of cancer cells to local and distant sites depends on a             
complex and poorly understood interplay between malignant cells and the          
cellular and non-cellular components surrounding them, collectively termed        
the tumour microenvironment. The most abundant cell type of the tumour           
microenvironment is the fibroblast, which becomes corrupted by locally         
derived cues such as TGF-β1 and acquires an altered, heterogeneous          
phenotype (cancer-associated fibroblast, CAF) supportive of tumour cell        
invasion and metastasis. Efforts to develop new treatments targeting the          
tumour mesenchyme are hampered by a poor understanding of the          
mechanisms underlying the development of CAF. 
Here we examine the contribution of microRNA to the development of           
experimentally-derived CAF and correlate this with changes observed in CAF          
derived from tumours. Exposure of primary normal human fibroblasts to          
TGF-β1 resulted in the acquisition of a myofibroblastic CAF-like phenotype.          
This was associated with increased expression of miR-145, a miRNA          
predicted ​in silico to target multiple components of the TGF-β signaling           
pathway. miR-145 was also over-expressed in CAF derived from oral          
cancers. Over-expression of miR-145 blocked TGF-β1-induced      
myofibroblastic differentiation and revert CAF towards a normal fibroblast         
phenotype.  
We conclude that miR-145 is a key regulator of the CAF phenotype, acting in              
a negative feedback loop to dampen acquisition of myofibroblastic traits, a           
key feature of CAF associated with poor disease outcome.  
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Introduction 
It is becoming increasingly apparent that interactions between malignant         
cells and the cells and other constituents of the tumour microenvironment           
play a key role in disease outcome (1). Fibroblasts are the most numerous             
cells in the tumour microenvironment and act to modulate both cancer cell            
behaviour and the host immune responses by remodelling the extracellular          
matrix (ECM) and secreting a host of soluble factors able to interact with             
nearby cellular receptors via cell autonomous and subservient mechanisms         
(2). The phenotypes of the fibroblasts surrounding a tumour (collectively          
termed cancer associated fibroblasts; CAF) are complex and varied, but          
certain CAF features are strongly associated with cancer cell dissemination          
and poor outcome (3). The best characterized of these is the presence of             
‘myofibroblastic’ CAF; cells expressing alpha smooth muscle actin (αSMA)         
which at least superficially resemble myofibroblasts found transiently in         
healing wounds (4). Myofibroblastic CAF are contractile, secretory cells that          
generate an altered extracellular matrix and are generally accepted to          
contribute to an extracellular milieu supportive of cancer cell invasion and           
metastasis (2). The presence of αSMA-rich CAF is correlated with poor           
outcome in a number of cancers, suggesting a key role in disease            
progression (3,5–7). The source of myofibroblastic CAF is controversial but at           
least some are likely to arise from differentiation (or ‘activation’) of resting            
fibroblasts provoked by signals, such as TGF-β1, released from cancer and           
inflammatory cells recruited to the tumour microenvironment (8).  
Despite the wealth of data supporting a role for CAF in contributing to tumour              
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metastasis, little is known of the mechanisms underlying CAF development          
from resident stromal fibroblasts. Here, we applied an ​in silico approach to            
identify a microRNA, miR-145, found predominantly in mesenchymal cells (9),          
putatively able to target components of the TGF-β1 signalling pathway and           
examined the effects of this microRNA on the phenotype of normal           
fibroblasts, myofibroblasts and CAF. Expression of miR-145 was induced by          
exposure of normal fibroblasts to TGF-β1 and was also elevated in CAF.            
Overexpression of miR-145 inhibited the development of myofibroblastic        
traits and stromal-epithelial interactions, indicating the existence of a         
miR-145/TGF-β negative feedback loop in myofibroblasts and CAF. This         
suggests the possibility of exploiting this therapeutically to reduce         
pro-tumourigenic traits of stromal fibroblasts.  
 
Materials and methods 
 
Routine tissue culture:​ Primary normal oral fibroblasts (NOF) were isolated          
from informed consenting patients undergoing wisdom tooth extraction at         
the Charles Clifford Dental Hospital (Sheffield Research Committee ethics         
permission 09/H1308/66) as described previously (10). CAF were isolated         
from oral squamous cell carcinoma (OSCC) of consenting patients at the           
University of Campinas (MCA) and the University of Glasgow prior to the            
introduction of current ethical requirements (11–13). In addition to NOF          
cultures, normal human oral fibroblast cultures NHOF-1 and NHOF-5 were          
obtained from the University of Peridanya, Kandy, Sri Lanka as described           
4 
 
Page 4 of 31Carcinogenesis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
previously (14). Human primary dermal fibroblasts (Promocell) were a kind gift           
from Dr Simon Whawell. H357, a cell line isolated from tongue OSCC (15),             
was obtained from ATTCC and cell identity was confirmed by satellite           
tandem repeat (STR) analysis of cells within 10 passages. All cells were            
routinely cultured in Dulbecco’s modification of Eagle’s medium (DMEM),         
supplemented with 10% (v/v) foetal bovine serum (FBS) and 2 mM           
L ​-glutamine, without antibiotics at 37 °C with 5% (v/v) CO​2​. ​Primary           
fibroblasts were used within 3-9 passages. For TGF-β1 treatment, oral          
fibroblasts were seeded at 250,000 cells per well in a six well plate, allowed              
to settle before being serum starved for 24 h before treatment with 5 ng/ml              
TGF-β1 for 24-96 h (as indicated in individual figure legends) in serum free             
DMEM supplemented with 2 mM L-glutamine.  
 
Transfection:​ Synthetic oligonucleotide premiRs (premiR-143, premiR-145 or       
negative premiR; 50 nM) and siRNAs (versican siRNA and negative siRNA; 50            
nM) (all Life Technologies) were transiently transfected into the primary oral           
fibroblasts using Oligofectamine (Life Technologies) in Opti-MEM (Life        
Technologies). Transfection was performed before or after TGF-β1        
treatment. Conditioned media (serum-free DMEM supplemented with 2 mM         
L-glutamine) were collected after 24 h for subsequent use in transwell           
migration assays. 
 
Immunocytochemistry:​ To visualise αSMA stress fibres, 250,000 fibroblasts        
were seeded on glass coverslips in six-well plates. After         
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treatments/transfections they were fixed with methanol for 10 min,         
permeabilised by using 4mM sodium deoxycholate and incubated with a          
FITC-conjugated anti-human αSMA mouse antibody (clone 1A.4; 1:100;        
Sigma-Aldrich Cat#F3777, RRID:AB_476977) for 12 h at 4 °C, following          
blocking of non-specific binding sites in 2.5% (w/v) bovine serum albumin           
(BSA) in phosphate buffered saline (PBS) for 30 min. Coverslips were washed            
twice with PBS, mounted using mounting media containing        
4',6-diamidino-2-phenylindole ​(​DAPI; Vectorshield), viewed using a Ziess       
Axioplan 2 fluorescence light microscope at 40x and imaged using Proplus           
7.0.1 image software. 
 
Contractility assay: Fibroblast-populated collagen gels were prepared as        
previously described (16) using transiently transfected or un-modified normal         
human primary oral fibroblasts as described in individual figure legends. 
 
Quantitative Real Time PCR: Total RNA was extracted from pelleted          
fibroblasts using the RNeasy (Qiagen) kit according to the manufacturer’s          
instructions. RNA was quantified using a Nanodrop 1000 spectrophotometer         
(Thermo). RNA (100 ng) was reverse transcribed using the high capacity           
cDNA Reverse Transcription kit (Applied Biosystems), according to the         
manufacturer’s protocol. Specific mature microRNAs were reverse       
transcribed from 10 ng RNA using specific Taqman reverse transcription          
microRNA probe/primers for mature miR-143, miR-145 and the small nuclear          
RNA RNU48 as a reference (Applied Biosystems). Total or specific          
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miRNA-derived cDNA was subsequently used as a template for SYBR green           
or Taqman real time quantitative PCR amplification (7900HT fast Real          
Time-PCR system, Life Technologies). Sequences of primers used for SYBR          
analysis (Sigma) were as follows: U6 Forward (F) 5’         
CTCGCTTCGGCAGCACA3’, U6 Reverse (R)    
5’AACGTTCACGAATTTGCGT3’, αSMA F ​5’GAAGAAGAGGACAGCACTG3’,    
αSMA R 5’TCCCATTCCCACCATCAC3’, fibronectin-1 with extra domain A        
(FN1-EDA) 5’TGGAACCCAGTCCACAGCTATT3’, FN1-EDA R    
5’GTCTTCTCCTTGGGGGTCACC3’, collagen 1A (COL1A1) F     
5’GTGGCCATCCAGCTGACC3’, COL1A1 R   
5’AGTGGTAGGTGATGTTCTGGGAG3’ connective tissue growth factor     
(CTGF) F 5’ GGGAAATGCTGCGAGGAGT 3’, CTGF R 
5’AGGTCTTGGAACAGGCGCTC 3’, matrix metalloproteinase 2 (MMP2) F 5’ 
AATAATTCCGCTTCCAGGGCACATCC 3’, MMP2 R 5’     
TTATTGCGGTCGTAGTCCTCAGTGGT 3’. Versican isoform specific Taqman      
probes (Applied Biosystems) were used to assess the expression of V0 and            
V1 versican isoform transcripts. Relative expression was calculated using the          
ΔΔCT method (17) normalised to endogenous controls U6 (SYBR green), or           
RNU 48 (Taqman). All qPCR was carried out according to best-practice MiQE            
guidelines (18). 
 
Immunoblotting: Total protein lysates were prepared in       
radio-immunoprecipitation assay (RIPA) buffer supplemented with complete       
mini protease inhibitor cocktail (Roche) and benzonuclease (Sigma). Protein         
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lysates (20-30 µg) were resolved by 3-8% (v/v) SDS-polyacrylamide gel (Life           
Technologies) electrophoresis (SDS-PAGE) in Tris-acetate buffer (Life       
Technologies). Proteins were transferred onto a nitrocellulose membrane        
(Millipore) by wet transfer or iBlot dry transfer (Invitrogen), and incubated in            
blocking solution (5% (w/v) milk powder and 3% (w/v) bovine serum albumin            
(BSA) in Tris buffered saline (TBS) with 0.05% (v/v) Tween 20 (TBS-T)) for 1 h.               
Mouse monoclonal anti-human αSMA (clone 1A4; Sigma-Aldrich       
Cat#A2547, RRID:AB_476701), goat polyclonal anti-human versican (R&D       
systems), or monoclonal rabbit anti-human GAPDH (Sigma-Aldrich       
Cat#G9295, RRID:AB_1078992) antibodies were diluted (1:1000) in blocking        
solution and incubated with membranes at 4°C overnight. The membrane          
was washed 3 x 5 min with TBS-T, and subsequently incubated with a             
horseradish peroxidase-conjugated (HRP) secondary antibody (1:3000 in       
blocking solution), for 1 h at ambient temperature. The membrane was           
washed 3 x 10 min in TBS-T, and developed using enhanced           
chemiluminescence (Pierce).  
 
Migration and Invasion assays: Conditioned media collected from transfected         
and TGF-β1 (5 ng/ml) treated fibroblasts were centrifuged at 2,500 x ​g and             
the supernatant was placed into the bottom of a well of a 24-well plate. H357               
cells, previously serum-starved for 24 h, were resuspended into 0.1% (w/v)           
BSA in DMEM supplemented with L-glutamine (2 mM) and seeded at a            
density of 100,000 cells/well into the top of a transwell chamber (BD            
Biosciences). Transwells were coated with Matrigel (300 µg/ml; Corning) to          
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assess cell invasion. Cells were allowed to migrate for 36 h at 37°C and 5%               
(v/v) CO​2 in the presence of 1 mg/ml mitomycin C, to inhibit cell proliferation.              
Transwell chambers were swabbed to remove non-migrated cells in the top           
of the chamber and fixed in methanol for 10 min. Migrated cells were stained              
with 0.1% (w/v) crystal violet and imaged at four randomly selected fields of             
view per transwell at 40x magnification using a light microscope. Migrated           
cells were then counted using ImageJ.  
 
Statistical analyses:​ A paired two-tailed student’s t-test was used to test for            
statistical significance. A Mann Whitney U test (performed in GraphPad Prism           
6) was used to assess significance in differential gene expression in NOFs            
and CAF.  
 
Results 
TGF-β 1 stimulates pro-tumourigenic myofibroblast transdifferentiation 
The ability of TGF-β1 to induce myofibroblast transdifferentiation of primary          
human fibroblasts was examined using several established markers of the          
myofibroblast phenotype (19–23). Treatment of oral fibroblasts with TGF-β1         
(5 ng/ml) resulted in a time-dependent increase in the expression of αSMA,            
versican (VCAN, V0 isoform) and fibronectin 1 extra domain A (FN1-EDA)           
transcripts (Fig 1a-c), with a corresponding increase in αSMA protein levels           
and the appearance of αSMA-rich stress fibres (Fig 1d&e). This was           
associated with increased ability to contract collagen I lattices (Fig 1f), in            
keeping with previous reports (22). Conditioned medium from        
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TGF-β-induced myofibroblasts promoted more cancer cell migration and        
invasion than medium from untreated fibroblasts (Fig 1g&h). It is noteworthy           
that not all the different cultures of primary fibroblasts tested, obtained from            
different patients, responded equally to TGF-β1 (Fig S1). 
 
MicroRNA-145 is upregulated during myofibroblast transdifferentiation 
In order to begin to examine the molecular mechanisms underlying the           
TGF-β-induced acquisition of a pro-tumourigenic, myofibroblastic      
phenotype by primary fibroblasts, we carried out an ​in silico analysis to            
identify miRNA predicted to target components of the TGF-β1 signalling          
pathway, using a variety of online algorithms including DIANA         
(http://diana.cslab.ece.ntua.gr/). One of the candidate miRNA identified using        
this approach, miR-145, is predicted or functionally demonstrated in the          
literature to have numerous targets or putative targets in the TGF-β1           
pathway (Fig 2a), and was upregulated in response to TGF-β1 treatment in a             
number of NOF cultures analysed (Fig 2b) but with heterogeneity in response            
between different cultures. Having identified a putative role for miR-145 in           
fibroblast responses to TGF-β1, we next analysed the expression levels of           
mature miR-145 in a panel of ten NOF and ten CAF (isolated from patients              
with oral squamous cell carcinomas (14)), miR-145 expression was         
statistically significantly higher in CAF than in normal oral fibroblasts (Fig 2d).  
 
miR-145 inhibits myofibroblast differentiation in response to TGF-β 1 
In order to examine the effect of miR-145 on myofibroblast differentiation, a            
10 
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synthetic miRNA functionally mimicking mature miR-145 or a control,         
non-targeting miRNA, were transfected into primary oral fibroblasts and the          
effect on markers of the myofibroblastic phenotype was examined.         
Over-expression of miR-145 (Fig 3a) resulted in an almost complete abolition           
of the ability of TGF-β1 to induce αSMA transcript levels (Fig 3b) and a              
reduction of TGF-β-induced αSMA protein levels, as determined by         
immunoblotting (Fig 3c). No change in the basal level of αSMA was            
observed in response to miR-145 over-expression in the absence of          
TGF-β1. Overexpression of miR-143, a miRNA co-expressed with miR-145         
as part of a bicistronic cluster (24), resulted in a small decrease in the              
expression of αSMA transcript but had no effect on αSMA protein levels            
(Fig 3b&c). In keeping with th se findings, we observed a reduction in            
αSMA-positive stress fibres in response to TGF-β1 in fibroblasts         
over-expressing miR-145 (Fig 3d) and a modest, but significant, reduction in           
the ability of fibroblasts to contract collagen gels in response to TGF-β1            
compared to controls (Fig 3e). Similar results with regards to αSMA           
expression were obtained using dermal fibroblasts, suggesting the effects of          
miR-145 are not tissue specific (Fig 3f&g).  
We next examined the ability of miR-145 to influence extracellular matrix           
production, alterations of which are associated with myofibroblastic CAF         
(19,22,23,25). Heterologous over-expression of miR-145 was found to        
significantly and markedly decrease the expression of transcripts derived         
from a number of genes encoding components of the extracellular matrix,           
including FN1-EDA, connective tissue growth factor (CTGF), COL1A1, MMP2         
11 
 
Page 11 of 31 Carcinogenesis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
and both variants of VCAN expressed in oral fibroblasts (VCAN V0 and V1),             
and to block the upregulation of these genes in response to TGF-β1 (Figure             
4a-f). The down-regulation of VCAN was also observed at the protein level,            
as determined by immunoblotting (Fig 4g) with the level of knockdown           
approaching that achieved by VCAN-specific siRNA (Fig 4g).        
Over-expression of miR-143, previously reported to regulate VCAN        
expression (26), had no effect on either VCAN transcript or protein levels (Fig             
4g). Over-expression of miR-145 attenuated the ability of myofibroblasts to          
stimulate cancer cell migration and invasion in a paracrine manner (Fig 4h&i).            
Similar effects of miR-145 on the fibroblast phenotype were obtained with           
dermal fibroblasts (Fig 4j&k). 
 
miR-145 regulates the CAF phenotype 
Having established the ability of miR-145 to inhibit the acquisition of a            
CAF-like myofibroblastic phenotype in normal oral fibroblasts, we next         
examined its effects in CAF. Over-expression of miR-145 in CAF resulted in a             
decrease in both basal and TGFβ-induced αSMA, COL1A1 and FN1-EDA          
transcript levels (Fig 5a-c) and a reduction in the ability of TGF-β1 to induce              
the formation of αSMA-rich stress fibres (Fig 5d). As observed in normal            
fibroblasts, miR-145 overexpression was able to inhibit TGF-β-induced        
αSMA levels in all the CAF cultures analysed (Fig 5e and Fig S2a-c), and              
reduced both basal and TGF-β-induced VCAN protein expression (Fig 5e).          
Over-expression of miR-145 in CAF inhibited paracrine stimulation of cancer          
cell migration in two of the four CAF cultures tested (Fig 5f).  
12 
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Discussion 
The molecular mechanisms underlying the development of CAF from resident          
stromal fibroblasts are poorly understood, hampering the development of         
stromally-directed therapies. Here we identify miR-145 as a key regulator of           
the differentiation of myofibroblastic CAF from resting fibroblasts. We provide          
evidence that miR-145 levels are elevated in the majority of CAF isolated            
from oral squamous cell carcinomas compared to normal resting oral          
fibroblasts, and that induction of a myofibroblastic CAF-like phenotype ​in          
vitro results in induction of miR-145 expression. Furthermore, we show that           
miR-145 suppresses cytoskeletal and matricellular markers of myofibroblast        
activation, and paracrine stimulation of cancer cell migration and invasion,          
suggesting miR-145 up-regulation may serve to limit pro-tumourigenic,        
myofibroblastic differentiation in the tumour microenvironment. 
Whilst tumour-suppressive effects of miR-145 have been described in both          
tumour cells and fibroblasts (27–30), two recent studies suggested that          
miR-145 is restricted to, or at least significantly enriched in, cells of            
mesenchymal origin (9,31). In keeping with this, functions have been ascribed           
to miR-145 in a variety of mesenchymal cells, including smooth muscle cells            
and fibroblasts (32–36). In both of these cell types miR-145 is most            
commonly described as having the ability to promote differentiation, although          
a very recent study demonstrated that the effects of miR-145 on the vascular             
smooth muscle cell (VSMC) phenotype are context-specific, and that         
miR-145 is able to inhibit responses to TGF-β1, limiting the differentiation of            
13 
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VSMCs (36). This is consistent with our findings, in which we observe            
miR-145 levels to increase in response to TGF-β1 but to down-regulate           
numerous target genes induced by TGF-β1, thereby inhibiting the         
development of a myofibroblastic phenotype. In contrast to other studies          
(33–35), however, we found no evidence of miR-145 having the ability to            
induce myofibroblast markers in the absence of TGF-β1; indeed in          
tumour-derived CAF, miR-145 reproducibly reduced the basal levels of both          
cytoskeletal and matricellular myofibroblast markers. These conflicting       
results may be the result of species differences or the use of embryonic             
versus adult fibroblasts, but also suggests a degree of complexity          
characteristic of mechanisms regulating the actions of TGF-β1, likely         
reflecting the need to tune responses to the dynamic tissue          
microenvironment. It is noteworthy that our ​in silico analysis and          
unpublished data (de Oliveira et al, data not shown) indicates that miR-145            
may target the receptors and signaling components of other TGF-β1-related          
molecules, including activin A and bone morphogenetic proteins (BMPs),         
suggesting miR-145 may play a role in regulating cellular responses to these            
stimuli in addition to TGF-β1; we speculate that this pleiotropy may           
contribute to the complex and contradictory functions reported for miR-145          
in fibroblasts and smooth muscle cells. 
TGF-β1 signalling within stromal fibroblasts plays a crucial role in          
determining fibroblast responses to local cues such as ECM remodeling, and           
as such is subject to multiple layers of regulation (reviewed in (37)).            
Dysregulation of the TGF-β1 pathway, such as TGF-β1 overexpression and          
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loss of function of TGFβ receptor II (TGF-βRII) in fibroblasts, promotes           
tumourigenesis in adjacent epithelial cells and malignant progression (38–40).         
A variety of mechanisms exist to regulate TGF-β1 signalling, including          
negative feedback, exemplified by the role of SMAD7, which is induced by            
TGF-β1 but limits its downstream effects by negatively regulating the          
canonical signaling pathway via SMAD3/4 (41). Our data suggests miR-145          
function in a similar manner by negatively regulating the responses of stromal            
fibroblasts to TGF-β1.  
Myofibroblastic differentiation is a complex process regulated by both         
intrinsic and extrinsic cues. Among extrinsic cues, the ECM plays a           
prominent role, both through interaction of cells with individual components          
and by mechanical forces imposed by the ECM. In this study, we provide             
evidence that miR-145 reduces the synthesis of a variety of ECM           
components in the presence and absence of TGF-β1. What is yet to be             
determined, however, is whether these are direct or indirect targets of           
miR-145. Of those targets studied, only CTGF is reported to be directly            
targeted by miR-145 (42); we are currently seeking to validate this in primary             
fibroblasts. miR-145 has several documented targets in the TGF-β pathway          
including SMAD3 (43) and TGF-βRII (36), down-regulation of which may          
influence the production of ECM components. We propose that miR-145          
regulates responses to TGF-β1 by targeting multiple components of the          
pathway, possibly differentially in response to yet undetermined additional         
context-specific cues. In the tumour microenvironment, this confers on         
miR-145 the ability to reduce the myofibroblastic, pro-tumourigenic CAF         
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phenotype. 
Here we have outlined a key role for mesenchymal miR-145 in a TGF-β1             
feedback loop in stromal fibroblasts. Up-regulated by TGF-β1, miR-145 is          
able to dampen TGF-β1 mediated myofibroblast transdifferentiation and        
consequential pro-tumourigenic effects in fibroblasts. This raises the        
possibility that miR-145 could be exogenously targeted to the tumour          
microenvironment to attenuate the pro-tumourigenic myofibroblastic      
phenotype of CAF. It may also hold promise in other contexts in which             
myofibroblasts play a role, such as fibrotic disorders. miRNA-mediated         
therapies are currently in clinical trials (reviewed in (44)) and recent           
developments in miRNA delivery techniques have realised the possibility of          
specifically delivering miRNAs to specific tissue microenvironments (45).  
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Figure legends 
Figure 1. TGF-β1 induces myofibroblastic features in primary human         
fibroblasts. ​Primary fibroblasts were treated with TGF-β1 (5 ng/ml) or serum           
free DMEM for 24-96 h as indicated. RNA was extracted, reverse transcribed            
and subjected to qPCR to determine the transcript levels ofαSMA (a), VCAN             
V0 (b) or FN1-EDA (c). Total cell lysates were prepared and immunoblotted            
for αSMA (d). Following treatment with TGF-β1 for 48 h, cells were fixed in              
methanol and αSMA visualized using a FITC-conjugated anti-αSMA        
antibody (e). The ability of fibroblasts treated with TGF-β1 for 48 h to             
contract collagen 1 was examined compared to serum free DMEM treated           
controls (f). Conditioned medium collected from cells exposed to TGF-β1 for           
48 h was used in a transwell assay to assess the migration (g) or invasion               
through Matrigel (h) of H357 cancer cells. ****p<0.0001, ***p<0.001, **p<0.01          
assessed using a paired, two tailed student’s t-test. n=3. 
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Figure 2. miR-145 has multiple putative targets in TGF-β signaling          
pathways and is up-regulated by TGF-β1. ​Analysis of potential targets of           
miR-145 using DIANA reveals a number of putative targets in the TGF-β1            
signalling pathway as well as other genes associated with myofibroblast          
differentiation (a). NOF were serum starved for 24 h before being exposed to             
TGF-β1 (5 ng/mL) or vehicle for 24 h. Levels of miR-145 were analysed by              
conventional qPCR in 4 independent NOF cultures treated with TGF-β1 or           
vehicle as described (b). miR-145 levels were assessed by qPCR in 10 NOF             
cultures and 10 CAF cultures (c). **p<0.01, *p<0.05 using a paired, two tailed             
student’s t-test (b) and D using Mann-Whitney test (c). n=3 (b). 
 
Figure 3. miR-145 overexpression inhibits myofibroblast differentiation.       
Proliferating NOF were transfected with 50 nM synthetic premiR-143,         
premiR-145 or a control, non-targeting premiR (negative premiR), incubated         
for 24 h before being exposed to TGF-β1 (5 ng/mL) or serum free DMEM              
control for a further 48 h. RNA was extracted and resulting cDNA subjected             
to qPCR for mature miR-145 (a) or αSMA (b). Total cellular lysate protein             
from cells transfected as described was immunoblotted for αSMA (c), or           
cells were fixed in methanol and stress fibres visualised using          
FITC-conjugated anti-αSMA antibody (d); additionally transfected cells were        
seeded into collagen I gels and their ability to contract the gels in following              
treatment with TGF-β1 (5 ng/mL) or vehicle control for 48 h determined (e).             
Human dermal primary fibroblasts (HDF) were transfected with miR-145 and          
treated with TGF-β1, as above. αSMA transcript levels were assessed by           
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qPCR (f) and protein by immunoblotting (g) ****p<0.0001, ***p<0.001,         
**p<0.01, *p<0.05 using a paired, two tailed student’s t-test. n=3. 
 
Figure 4. miR-145 alters ECM deposition by fibroblasts. ​Proliferating NOF          
were transfected with 50 nM synthetic premiR-145 or a control, non-targeting           
premiR (negative premiR), incubated for 24 h before being exposed to           
TGF-β1 (5 ng/mL) or serum free DMEM control for a further 48 h. RNA was               
extracted and resulting cDNA subjected to qPCR for FN1-EDA (a), CTGF (b),            
COL1A1 (c), MMP2 (d), and VCAN transcripts V0 and V1 (e, f). Total cellular              
lysate proteins from cells transfected as described, or transfected for 24 h            
prior to TGF-β1 treatment with either miR-145 or a non-targeting miRNA,           
siRNA targeting VCAN or a non-targetting siRNA, were immunoblotted for          
VCAN and reprobed for GAPDH as a loading control (g). Conditioned           
medium was collected after 24 h incubation from NOF transfected as           
described and treated with TGF-β1 for 48 h. The media was changed for             
fresh low serum medium before conditioned medium was added to the lower            
chamber of a transwell assay, and H357 cells in reduced serum medium            
added to the top of the insert. Cells migrating across the insert were counted              
(h). The same procedure was followed with matrigel present in the insert (i).             
Human dermal primary fibroblasts (HDF) were transfected with miR-145 and          
treated with TGF-β1, as above. FN-EDA1 transcript levels were assessed by           
qPCR (j) and versican protein by immunoblotting (k), with a β-actin as in             
(duplicated from fig 3g) . ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 using a           
paired, two tailed student’s t-test. n=3. 
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Figure 5. miR-145 regulates the CAF phenotype. ​Proliferating CAF were          
transfected with 50 nM synthetic premiR-145 or a control, non-targeting          
premiR (negative premiR), incubated for 24 h before being exposed to           
TGF-β1 (5 ng/mL) or serum free DMEM control for a further 48 h. RNA was               
extracted and resulting cDNA subjected to qPCR for αSMA (a), COL1A1 (b)            
and FN1-EDA (c). Following treatment with TGF-β1 for 48 h, CAF were fixed             
in methanol and αSMA visualized using a FITC-conjugated anti-αSMA         
antibody (d), or total cell lysates were prepared and immunoblotted for           
αSMA and VCAN; β-actin served as a loading control (e). CAF were            
transfected with miR-145 mimic or non-targeting control and conditioned         
medium collected before being added to the lower chamber of a transwell            
assay, and H357 cells in reduced serum medium added to the top of the              
insert (schematic, f). Cells migrating across the insert were counted.          
****p<0.0001, ***p<0.001, **p<0.01 using a paired, two tailed student’s t-test.          
n=3. 
 
Figure S1. TGF-β1 induces αSMA to differing extents in different          
fibroblast cultures. ​Independent ​primary fibroblast cultures (NOF1-4) were        
treated with TGF-β1 (5 ng/mL) or serum free DMEM for 48 h. RNA was              
extracted, reverse transcribed and subjected to qPCR to determine the          
transcript levels of αSMA. ****p<0.0001, ***p<0.001, **p<0.01 assessed        
using a paired, two tailed student’s t-test. n=3. 
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Figure S2.  miR-145 inhibits TGF-β1-induced αSMA expression in CAF  
Three different proliferating CAF cultures (a-c; cultures indicated on graphs)          
were transfected with 50 nM synthetic premiR-145 or a control, non-targeting           
premiR (negative premiR), incubated for 24 h before being exposed to           
TGF-β1 (5 ng/mL) or serum free DMEM control for a further 48 h. RNA was               
extracted and resulting cDNA subjected to qPCR for αSMA. ****p<0.0001,          
***p<0.001, **p<0.01 using a paired, two tailed student’s t-test. n=3. 
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